The core activity of Nouscom is the development of cancer vaccines, in particular neoantigen-based cancer vaccines for tumors with microsatellite instability.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Cancer immunotherapies using viral vectors and neoantigens, including an off-the-shelf therapy for dMMR/MSI tumors and a personalized neoantigen vaccine.
Personalized Cancer Vaccines
Personalized cancer vaccines based on patient-specific neoantigens from tumor mutanomes, with rapid manufacturing from biopsy to released product.
Off-the-Shelf Cancer Immunotherapies
Standardized cancer immunotherapies with shared frameshift neoantigens for dMMR/MSI tumors, used in combination with pembrolizumab and in clinical studies.
Targeted Oncolytic Viruses
Targeted armed oncolytic viruses for solid tumors, delivered locally or systemically, with immunomodulatory transgenes to enhance anti-tumor activity.